Voyager Acquisition Corp. II

S-1 filed

Voyager Acquisition Corp. II, a Cayman Islands exempted company, is conducting an initial public offering (IPO) of 22,000,000 units at $10.00 per unit, raising $220 million. Each unit includes one Class A ordinary share and a redeemable warrant. The company aims to complete a business combination in technology, fintech, or healthcare sectors. Proceeds will be held in a trust account, with underwriters retaining $0.70 per unit in discounts. The filing outlines redemption rights for public shareholders, potential warrant exercises, and a 45-day over-allotment option. The company has not yet identified a specific target and faces risks related to timing, dilution, and liquidity.

DRS/A amended

Voyager Acquisition Corp. II, a Cayman Islands exempted company, is conducting an IPO of 22,000,000 units at $10.00 per unit, raising $220 million. Each unit includes one Class A share and one-half of a redeemable warrant. The company aims to target technology, fintech, and healthcare sectors for its initial business combination. The filing includes details on trust account management, sponsor share conversions, and redemption rights for public shareholders. It also outlines underwriting terms, including deferred commissions and a 45-day over-allotment option.

DRS/A amended

Voyager Acquisition Corp. II, a Cayman Islands exempted company, is conducting an IPO to raise $175 million through the sale of 17.5 million units at $10 per unit. Each unit includes one Class A ordinary share and a right to receive 1/8 of a Class A share upon a business combination. The company aims to target healthcare sector opportunities and has not yet identified a specific target. The filing includes details on redemption rights, a trust account for proceeds, and plans for Nasdaq listing. The sponsor holds Class B shares convertible to Class A shares, with anti-dilution adjustments.

DRS filed

Voyager Acquisition Corp. II, a blank check company incorporated in the Cayman Islands, is preparing for its initial public offering (IPO) of 17,500,000 units at $10.00 per unit, raising $175 million. The company aims to merge with or acquire a business in the healthcare sector. Proceeds will be held in a trust account, with redemption rights for public shareholders tied to the completion of an initial business combination. The filing highlights risks related to the uncertainty of identifying a target, potential dilution from share conversions, and reliance on sponsor and underwriter commitments. The company is an emerging growth entity with reduced reporting requirements.